medwireNews: A short course of hypofractionated proton beam therapy given alongside temozolomide may offer an improvement in overall survival for patients aged 65 years and older with a new diagnosis of glioblastoma, suggesting findings from a “hypothesis-generating” study.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © Lyudmila / stock.adobe.com
